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Abstract
Aims The purpose of this study was to evaluate the
effectiveness of a new, fixed, yet individualized dosing
regimen of activated prothrombin complex concentrate
factor VIII inhibitor bypassing activity (FEIBA) for
warfarin reversal in the setting of a life-threatening bleeding
in a secondary care center.
Methods In this report we present a retrospective chart
review of 72 patients who received FEIBA and 69 patients
who received fresh-frozen plasma (FFP) to reverse the
effects of warfarin in a setting of a life-threatening bleeding.
In the FEIBA cohort, patients received 500 units of FEIBA
when the initial INR was <5 or 1,000 units of FEIBA when
initial INR was ≥5.
Results FEIBA administration resulted in lower subsequent
INR when compared with FFP and shorter time elapsed
from drug administration to an INR ≤1.4 when compared
with FFP. No significant differences in survival or in the
length of hospital stay were observed. A higher FEIBA
dose induced a bigger decrease in INR than the lower dose.
We observed five adverse events (7%) that could potentially
be related to FEIBA administration.
Conclusions The presented dosing regimen results in safe
reversal of warfarin-induced coagulopathy, which appears to
be faster and more profound than following FFP. Moreover,
the use of activated PCC (FEIBA) does not appear to carry
an increased risk of thrombotic events when compared to the
rate reported for several non-activated PCC preparations.





FEIBA factor VIII inhibitor bypassing activity
FFP fresh-frozen plasma
INR international normalized ratio
PCC prothrombin complex concentrate
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Currently 1–2% of the US and European populations are
receiving oral vitamin K antagonists, such as warfarin
[1–3], which places them at an estimated increased risk of
hemorrhage of 1.0% to 15.0% [4–6]. Moreover, from
0.3% to 1% of patients receiving oral anticoagulants die
as a result of a major hemorrhage [2, 7]. In case of
intracranial hemorrhage, the mortality increases up to 60%
[7]. Therefore, rapid and efficient warfarin reversal in the
setting of an emergent, life-threatening bleeding is
needed.
Warfarin and other vitamin K antagonists inhibit the
γ-carboxylation of coagulation factors VII, IX, X and II.
Vitamin K restores their γ-carboxylation; however, several
hours are required before levels assuring normal hemostasis
are reached [7]. Moreover, in case of INR ≥4.5, vitamin K
administration does not appear to prevent the incidence of
major hemorrhages [8]. Therefore, the rapid reversal of
warfarin-induced coagulopathy requires administration
of biologically active coagulation factors [9]. Many experts
still prefer fresh-frozen plasma (FFP) for the reversal of
warfarin effects, with prothrombin complex concentrate
(PCC) and recombinant activated factor VII as alternatives
[9, 10]. In the US, FFP remains the mainstream treatment,
despite being suboptimal due to incomplete correction of
coagulopathy, slow administration, increased risk of infec-
tion, and delays due to thawing and transport from the
blood bank [1, 11–15]. Moreover, FFP transfusion is
associated with transfusion-related acute lung injury and
transfusion-associated circulatory overload [16, 17]. There-
fore, PCC is emerging as an alternative to FFP in patients with
life-threatening bleeding [9, 18, 19]. Moreover, while Jeho-
vah’sWitnessesrefusetreatmentwithFFPbecauseofreligious
beliefs, treatment with purified proteins derived from plasma is
acceptable, making PCC the only treatment modality for this
group [20].
PCC was initially recommended at the dose of
50 units/kg [21], but Evans et al. demonstrated that a
dose of 30 units/kg is sufficient to normalize major
bleeding [6]. The European Stroke Initiative recommen-
ded a wide range of PCC doses between 10–50 units/kg
[18]. Dose variability depends on the source of PCC, since
manufacturers label PCC according to factor IX content,
but the concentrations of the other vitamin-K-dependent
factors (prothrombin, VII, X, protein C and protein S) as
well as antithrombin and heparin (added to reduce
thrombogenicity) vary significantly [2]. Therefore, many
guidelines recommending PCC administration lack rec-
ommendations regarding the dosing regimen [9, 10, 18,
19]. In particular, the recommendations do not specify
whether to use non-activated PCC preparations or, on the
contrary, activated PCC preparations, known as anti-
inhibitor coagulant complex or FEIBA (factor VIII
inhibitor bypassing activity; available as FEIBA VH or
Autoplex T) [22]. A recent trial concluded that an
"individualized" dosage regimen of PCC based on target-
INR, initial-INR and patient body weight is significantly
more effective in reaching target INR than a fixed dose
[23]. While PCC appears to be superior to FFP in many
aspects [1, 11–15], its administration carries a 6% risk of
thrombosis [6], which depends on the presence of
activated factor VII [7, 22, 24, 25].
While Beriplex (CSL Behring) is a non-activated four-
factor PCC preparation widely studied in Europe for
warfarin reversal, it is not on the American market,
where experience with PCC use in warfarin reversal is
very limited. Based on the need for a rapid and effective
warfarin reversal in the setting of a life-threatening
bleeding, we decided to use a low dose of activated
PCC or FEIBA rather than the higher doses of non-
activated three-factor PCC preparations available on the
American market, such as Profilnine (Grifols) or Bebulin
VH. Three-factor PCCs are known to be less effective in
INR reversal than four-factor PCCs, such as Proplex T
(Baxter) used by Lankiewicz et al. [13], which unfortu-
nately is no longer available in the US. A review of the
literature and clinical data demonstrate that FEIBA has a
low incidence of thrombosis that is equivalent to that of
recombinant factor VIIa, another new therapeutic modal-
i t yi nw a r f a r i nr e v e r s a l[ 22] .A tt h es a m et i m e ,F E I B Ah a s
an excellent record in pathogen safety and clinical
tolerability [22].
We have followed the example of Yasaka et al., who
used a PCC preparation rich in factor VII (“PPSB-HT
Nichiyaku”) that required a much smaller dose than the
recommended one to achieve hemostasis [26]. Moreover,
rather than weight-adjusting the dose, Yasaka et al. opted
for a fixed dose of 500 units, which rapidly reversed INR to
<1.5 in 25 out of 26 patients [26]. However, if the initial
INR was ≥5, the dose of 500 units of PCC was often
inadequate [26].
We have established a new, simplified dosing
protocol of activated PCC (FEIBA) using a fixed, yet
individualized dose (Fig. 1). The patients are divided
into two groups: those with INR <5 receive 500 units of
FEIBA, while those with INR ≥5 receive 1,000 units of
FEIBA. FEIBA is always accompanied by 10 mg of vitamin
K administered i.v., which is necessary to maintain INR
reversal for 12–24 h [27]. In the present report, we
retrospectively compared the outcomes of 18 months of
using this protocol with the standard FFP regime for warfarin
reversal that was used in the year previous to the introduction
of the FEIBA protocol.
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FEIBA and FFP
Activated PCC FEIBA VH (vapor heated) anti-inhibitor
coagulant complex was purchased from Baxter (Westlake
Village, CA) in two nominal potencies: 500 units and 1,000
units per vial. However, the vials do not always contain the
exact amount of the drug, accounting for some dose
variability (Table 1). Lyophilized FEIBA and the diluent
vial were kept at 2–4°C. They were warmed to room
temperature before reconstitution, which required ~15 min.
FEIBA was administered i.v. over the course of 10 min in a
total volume of 20 ml.
Matched FFP obtained from local blood bank was thawed
and typed, which takes ~30 min. One unit of FFP (200 ml) was
administered i.v. over the course of 1–2 h. The total amount of
FFPtoadministerwasdeterminedempirically(median2units).
Fig. 1 Deaconess protocol for the use of activated PCC in warfarin reversal
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The Deaconess protocol for warfarin reversal using FEIBA
(Fig. 1) was approved by the Pharmacy and Therapeutic
(P&T) Committee of the Deaconess Health System in May
2007. The definition of life-threatening bleeding was left to
the physician’s discretion. Patients with life-threatening
bleeding received 500 units of FEIBA if their INR was <5
and 1,000 units of FEIBA if their INR was ≥5. The INR was
repeated 30 min after administration, and a second dose
of 500 units of FEIBA was indicated if INR remained >1.5.
Vitamin K (10 mg) was administered concomitantly with
FEIBA [9, 27]. The protocol also included warnings, con-
traindications and monitoring parameters. Evaluation for
thrombotic complication was to be carried out based on
clinical suspicion. In September 2007, the P&T committee
determined that the attending physician should determine if
the second dose is clinically necessary to avoid overuse.
Study design
The Deaconess institutional review board approved our
study without the need for informed consent because of its
retrospective nature. Patient data had been depersonalized
in order to prevent patient identification according to the
Health Insurance Portability and Accountability Act
requirements. All authors had full access to the study data.
We extracted information regarding patient age, sex, race,
medical diagnoses including indication for warfarin, indica-
tion for warfarin reversal, initial hemoglobin concentration,
pretreatment INR, posttreatment INR, time between drug
administration and an INR ≤1.4, length of hospital stay and
outcome. As reported by other studies [23], it was difficult to
predict true reversal time due to confounding factors that
prevent INR from being repeated within 30 min as planned in
the protocol. Allthrombotic eventsafter FEIBA administration
were considered potentially significant.
The primary endpointinthis study wasINR normalization.
Since INR is sensitive to factor VII, INR may be corrected
with persistent coagulopathy because of the lower levels of
factor IX. Therefore, Makris suggested that any study of PCC
effectivity needs to document whether the bleeding has
stopped [2]. Cessation of bleeding is harder to assess when
it is in an enclosed space, as in intracranial hemorrhage.
Therefore, a secondary endpoint in our study was the
survival of patients. However, especially in case of patients
with intracranial hemorrhage, death may have occurred
regardless of achieving hemostasis.
Statistical methods
We performed statistical analysis using the Sigma Plot
v.11.0 software package. Numerical data were compared
with Student’s t-test and expressed as mean value.
Whenever the data failed the normality test and/or equal
variance test, they were compared using the Mann-Whitney
rank sum test and expressed as a median value. Frequencies
of categorical data were compared with the chi-square test
with Yates correction for continuity. Whenever more than
20% of the expected values in the contingency tables were
Table 1 Breakdown of patients treated with FEIBA and FFP according to the initial INR values
Measured parameter FEIBA FFP p value
INR <5 (n=51) INR ≥5 (n=21) Total (n=72) INR <5 (n=54) INR ≥5 (n=15) Total (n=69)
Age 75(45–90) 76(51–95) 75(45–95) 78(32–91) 77(36–88) 77(32–91) 0.479
Sex 65.3%M 52.2%M 61.1%M 44.4%M 46.7%M 44.9%M 0.079 §
34.7%F 47.8%F 38.9%F 55.6%F 53.3%F 55.1%F
Median INR at admission 2.6(1.2–4.9) 12.8(5.0-∞) 3.3(1.2-∞) 2.5(1.3–4.8) 7.4(5-∞) 2.9(1.3-∞) 0.104
% of patients with INR <5 at admission 100% 0% 70.8% 100% 0% 78.3% 0.207
Median INR after drug administration 1.4(1.1–3.2) 1.5(1.1-∞) 1.5(1.1-∞) 1.6(1.0–3.2) 2.0(1.5–4.8) 1.6(1.0–4.8) 0.046
% of patients with INR ≤1.4 following drug
administration
51.1% 42.9% 50.7% 28.2% 7.7% 33.3% 0.017 §
Median INR drop 1.2(-0.1–3.4) 11.3(0-∞) 1.8(-0.1-∞) 0.8(0–3.2) 11.6(1.2-∞) 1.0(0-∞) 0.014
Mean hemoglobin at admission (g/dl) 12.0±3.5 9.3±3.3 11.1±3.7 11.1±2.8 10.9±2.6 11.1±2.8 0.870
Dose administered (units)
* 504±19 999±40 662±234 2(1–11) 4(2–5) 2(1–11) n/a
% of patients with initial 1,000 units FEIBA
dose
0% 100% 31.9% n/a n/a n/a n/a
% of patients with additional drug dose 16.3% 21.2% 18.1% 20.4% 13.3% 18.8% 0.923 §
Median time from drug administration
to measurement of INR <1.4 (h)
2.0(0-∞) 4.8(0-∞) 2.0(0-∞) 23.7(2-∞) 29.2(12.5–50.9) 25.2(2-∞) 0.006
% of patients with ICH 46.9% 21.7% 38.9% 9.3% 26.7% 13.0% <0.001 §
Median length of hospital stay (days) 6(1–20) 6(1–15) 6(1–20) 6(1–64) 5(1–17) 6(1–64) 0.521
Survival 79.6% 73.9% 77.8% 88.9% 85.7% 88.2% 0.545 §
*Mean for FEIBA, median for FFP. p values obtained by running tests comparing the total FFP group and the total FEIBA group
p measured with Mann-Whitney rank sum test unless otherwise indicated; § measured with chi-square test




Deaconess Health System services the urban Evansville
area as well as surrounding rural areas in southwestern
Indiana, southeastern Illinois and northwestern Kentucky.
Over 95% of all patients were white, while the race of the
remaining patients was not recorded in the files.
From April 2007 to October 2008, FEIBA was used to
reverse the effects of warfarin in 73 patients (Table 1).
Indications for warfarin therapy are listed in Table 2,w h i l e
indications for warfarin reversal are listed in Table 3.F i f t y -
one patients had INR <5, while 22 patients had INR ≥5. We
excluded one patient who erroneously received an excessive
dose (9,900 units) of FEIBA from the analysis.
In 2005 FEIBAwas not yet available in our hospital, and
FFP was administered to 332 patients regardless of the level
of bleeding severity. In order to obtain a control cohort
comparable to our FEIBA cohort, we excluded those
patients who did not fulfill the criteria set for FEIBA
administration. We included patients with intracranial
hemorrhage and acute bleeding in other locations associated
with rapidly deteriorating clinical status, as well as patients
who required reversal because of a surgical emergency. Our
control FFP cohort included 69 patients (21% of all patients
who received FFP, Table 1). Indications for warfarin
therapy are listed in Table 2, while indications for warfarin
reversal are listed in Table 3. Fifty-four patients presented
with INR <5, while 15 patients presented with INR ≥5.
Dosing of FEIBA
Fifty-one patients with INR <5 received 500 units, while 21
patients with INR ≥5 received 1,000 units of FEIBA
(Table 1). Twelve (16.7%) patients required a repeat dose
of 500 units, and one patient (1.4%) required two repeat
doses of 500 units of FEIBA for continued bleeding and
INR >1.5. (Table 1).
Effect of FEIBA on INR reversal
Whenever the bleeding site was accessible to observation, we
achieved hemostasis in surviving patients following FEIBA
administration. Following FEIBA administration INR
dropped to a median of 1.5 (Table 1). Over 50% of patients
had a subsequent INR ≤1.4. In one case of a patient with
atrial fibrillation, cancer and nicotine addiction presenting
with acute gastrointestinal bleeding, the administration of
1,000 units of FEIBA caused only a minimal drop of INR
from 10.1 to 9.3. Following administration of an additional
500 units, the INR dropped below 1.4. In the case of a
second patient with mitral valve replacement, INR was still
undetectable following administration of 1,000 units of
FEIBA. This patient died before administration of a second
dose.
Possible adverse events of FEIBA
FEIBA was found to be well tolerated. Five patients had
adverse events possibly related to FEIBA administration.
The first patient experienced a peri-operative myocardial
infarction 6 h after a craniotomy and 15 h after FEIBA
administration. This patient had multiple underlying and
acute medical conditions that placed her at risk for
myocardial infarction. The second patient experienced deep
vein thrombosis around a peripherally inserted central
catheter 2 weeks after FEIBA was administered. The third
patient experienced chest pain and had positive troponin
markers. It was determined that this patient was not having
an acute problem and received a cardiac workup after
discharge. The fourth patient also experienced positive
troponin markers without conclusive evidence of an acute
coronary event as established by the consulting cardiolo-
Table 2 Indications for warfarin treatment in the cohorts treated with either FEIBA or FFP
Indication FEIBA n =72 FFP n=69
INR <5 INR ≥5 total INR <5 INR ≥5 Total
Atrial fibrillation 61.2%(30) 34.8%(8) 52.8%(38) 38.9%(21) 33.3%(5) 37.7%(26)
Complicated atrial fibrillation 6.1%(3) 8.7%(2) 6.9%(5) 14.8%(8) 13.3%(2) 14.5%(10)
Atherosclerosis 6.1%(3) 21.7%(5) 11.1%(8) 1.2%(1) 20.0%(3) 5.8%(4)
Valve replacement 12.2%(6) 8.7%(2) 11.1%(8) 14.8%(8) 6.7%(1) 13.0%(9)
Thromboembolism 10.2%(5) 21.8%(5) 13.9%(10) 24.1%(13) 26.7%(4) 24.6%(17)
Other 4.1%(2) 4.3%(1) 4.2%(3) 5.6%(3) 0.0%(0) 4.3%(3)
Total 100%(49) 100%(23) 100%(72) 100%(54) 100%(15) 100%(69)
P=0.511 using chi-square with 5 degrees of freedom comparing the FEIBA group with the FFP group subdivided by indications
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hepatitis, and arrived non-responsive to the hospital. INR
was still undetectable following administration of 1,000
units of FEIBA. Before the second dose could be
administered this patient developed ventricular fibrillation.
Resuscitation was unsuccessful. No source of bleeding was
identified clinically, and no autopsy was performed.
Another patient who died following FEIBA administration
died 5 days later, likely as a direct consequence of
enterococcal urosepsis. Based on thorough analysis of the
patient’s underlying history, we consider that none of the
five events were directly related to FEIBA administration.
Moreover, the patient who received the excessive dose of
9,900 units and was therefore excluded from statistical
analysis did not present any adverse effects.
A careful review of patients who received FFP did not
identify any adverse events, which may be related directly
to FFP application, with the exception of one patient who
developed a mild posttransfusion hypersensitivity reaction.
No thrombotic events were identified immediately following
FFP administration, while events following hospital
discharge were not amenable to analysis. One patient
suffered an MI 1 week following FFP administration, but
taking into account his history of coronary artery disease,
FFP administration was unlikely to be the direct cause of
this event.
Patient outcomes
Fifty-six of 72 patients treated with FEIBA (77.8%) survived
the bleeding episode, indicating successful hemostasis. There
was no difference in survival in the group with initial INR ≥5
compared with the group with initial INR <5 (P=0.813,
chi-square test). Of the 16 patients who did not survive, 10
wereadmittedforintracranialbleeding,1hadseveretrauma,2
were admitted for gastrointestinal bleeding, and 3 had severe
bleeding at other locations, including a ruptured abdominal
aneurysm. Following FEIBA administration, six patients had
INR ≤1.4, and seven patients had INR >1.4. In the case of
three patients, INR following FEIBA administration was
not measured before death. Six of the surviving patients
(10.7%) were readmitted within 30 days, none of them
for reasons that could be considered adverse effects of
treatment with FEIBA.
Comparison ofpatientswho received FEIBAwiththe patients
who received FFP
We compared 72 patients who received FEIBA to 69 patients
who received FFP for similar indications. The two cohorts
were not significantly different with respect to their age
(Mann-Whitney ranksum test,P=0.479), sex (chi-square test,
P=0.079), indications for warfarin treatment (P=0.216,
chi-square test) and level of hemoglobin at admission
(Mann-Whitney rank sum test, P=0.870). However, the
indications for warfarin reversal were different (P=<0.001,
chi-square test), despite our efforts to remove non-life-
threatening cases during chart review of the FFP cohort.
While the initial INR values were not different (P=0.104,
Mann-Whitney rank sum test), FEIBAwas significantly more
effectiveinloweringINR(P=0.014,Mann-Whitneyranksum
test). Fifty percent of patients who received FEIBA had their
subsequent INR ≤1.4, while only 33% of patients who
received FFP had their subsequent INR ≤1.4 (P=0.017,
chi-square test). The time elapsed from the beginning of
administration of the drug to the next INR measurement
(P=0.006, Mann-Whitney rank sum test) was longer after
administration of FPP. However, the two cohorts did not
differ with respect to survival (P=0.545, chi-square test)
or length of the hospital stay (P=0.521, Mann-Whitney
rank sum test).
Comparison of patients with initial INR ≥5 who received
FEIBA versus patients with initial INR ≥5 who received
FFP
We have compared 21 patients with an initial INR ≥5 who
received FEIBA to 15 patients with an initial INR ≥5 who
received FFP. The two groups were not significantly
different with respect to their age (Mann-Whitney rank
sum test, P=0.479), sex (Fisher’s exact test, P=1.000),
indications for warfarin treatment (P=0.963, chi-square
Table 3 Indication for the reversal of warfarin effects with FEIBA and FFP
Indication FEIBA n=72 FFP n=69
INR <5 INR ≥5 Total INR <5 INR ≥5 Total
GI bleeding 18.4%(9) 34.8%(8) 23.6%(17) 24.1%(13) 33.3%(5) 26.1%(18)
Intracranial hemorrhage 46.9%(23) 21.7%(5) 38.9%(28) 9.3% (5) 26.7%(4) 13.0% (9)
Preoperative 18.4%(9) 4.3%(1) 13.9%(10) 46.3%(25) 6/7%(1) 37.8%(26)
Other 16.3%(8) 39.1%(9) 23.6%(17) 20.4%(11) 33.3%(5) 23.2%(16)
Total 100%(49) 100%(23) 100%(72) 100% (54) 100%(15) 100% (69)
P=0.025 using chi-square with 3 degrees of freedom comparing the FEIBA group with the FFP group subdivided by indication
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P=0.105) and indications for warfarin reversal (P=0.965,
chi-square test). While initial INRs were similar (P=0.501,
Mann-Whitneyranksum test), INRs following administration
ofeitherFEIBAorFFPweresignificantlylowerintheFEIBA
cohort (P=0.031, Mann-Whitney rank sum test). Following
FFP administration, only 1 out of 13 patients (7.7%) with
repeated INR had subsequent INR ≤1.4, while after FEIBA
administration, 9 out of 21 patients (42.9%) had their
subsequent INR ≤1.4 (P=0.051, Mann-Whitney rank sum
test). There were also no differences in the length of hospital
stay (P=0.246, Mann-Whitney rank sum test) or in survival
(P=0.683, Fisher’s exact test).
Comparison of patients receiving FEIBA according to the initial
INR value
We compared patients who received FEIBA with initial
INR <5 (n=49) with patients who received FEIBA with
initial INR ≥5 (n=23) (Table 1). The two groups were not
significantly different with respect to their age (P=0.408,
Student’s t-test), sex (P=0.420, chi-square test) or
indications for warfarin treatment (P=0.197, chi-square
test). Indications for warfarin reversal were different,
s i n c et h eg r o u pw i t hI N R< 5w a se n r i c h e di nc a s e so f
intracranial hemorrhage (P=0.019, chi-square test). The
level of hemoglobin at admission was significantly
higher (P=0.002, Student’s t-test) in the group with
INR <5 (11.9 g/dl) when compared with the group with
the initial INR ≥5( 9 . 0g / d l ) .
Patients with higher INR did not require more
additional FEIBA doses than patients with lower INR
(P=0.743, Fisher’s exact test). INR values following
FEIBA administration were similar (P=0.383, Mann-
Whitney rank sum test), but the INR drop (difference
between initial INR and subsequent INR) was higher in
the group with INR ≥5 (P<0.001, Mann-Whitney rank
sum test). No differences were observed in the time
elapsed from FEIBA administration to the measurement
of INR <1.4 (P=0.209, Mann-Whitney rank sum test), in
the length of hospital stay (P=0.952, Mann-Whitney rank
sum test) or survival (P=0.813, chi-square test).
Discussion
We demonstrated the effectiveness of a protocol based on
the administration of a fixed low dose of activated PCC
(FEIBA) that was individualized according to the initial
INR value. The need for additional doses of FEIBA was
low (~18%) regardless of the initial dose, indicating its
appropriateness. Moreover, we demonstrated that such a
low dosing of FEIBA induced faster and more profound
INR reversal than FFP. This effect was more pronounced in
the group that initially had an INR ≥5. This can be easily
explained by the fact that administration of 1,000 units of
FEIBA takes the same amount of time as administration of
500 units of FEIBA, while administration of several units
of FFP require a much longer period of time than
administration of the initial one or two units dose.
While no such comparison was done before for activated
PCC, Fredriksson et al. first reported that a non-activated
PCC preparation deficient in factor VII (Preconativ, Kabi)
reverses INR 4.6 times more rapidly than FFP with more
patients achieving INR normalization following PCC than
following FFP (65% versus 31%) [11]. We observed INR
normalization 12 times faster in the group receiving FEIBA
compared with FFP. Moreover, we saw INR normalization
in >50% of patients receiving FEIBA compared with 33%
of patients receiving FFP.
FFP remains the mainstream of warfarin reversal in the
US, despite the fact that PCC offers several advantages over
FFP [1, 11, 12]. A third alternative is provided by
recombinant factor VIIa [28, 29]. However, PCC restores
overall thrombin generation better than recombinant factor
VIIa and confers antifibrinolytic activity in warfarin-treated
patients [30, 31]. Nevertheless, there is a lack of uniform
guidelines for PCC administration [9, 10, 18, 19], consid-
erable variation in practice among clinicians [32] as well as
great variability in the composition of PCC preparations
[2]. In the absence of clear dosage recommendations, many
institutions establish their own dosing regimens. Since only
those PCC preparations that are rich in factor VII are
suitable for warfarin reversal, we explored the use of small
doses of activated PCC (FEIBA) containing activated factor
VII [22].
Several studies have addressed the safety and efficacy of
PCC. In one study, 93% of patients (n=43) administered
25–50 units/kg of PCC (Beriplex) in conjunction with
vitamin K achieved an INR ≤1.3 within 30 min, leading to
good efficacy in 98% of patients with only one adverse
event potentially related to PCC use [33]. In another study,
Lankiewicz et al. promoted the use of a weight-adjusted
dose of non-activated PCC (25–50 units of Proplex T/ kg)
in a cohort of 58 patients, reporting INR drop from a
median of 3.8 (1.4–52.8) to 1.3 (0.9–5.7) without any
adverse events [13].
A fixed dose regimen of non-activated PCC (Beriplex)
was used at Eastbourne District General Hospital, where
21 patients were treated with fixed doses of 500, 1,000
and 1,500 units of PCC. However, there were no
reported correlations between the dose administered and
INR at admission and/or the clinical severity of bleeding
[19]. Since Yasaka et al. demonstrated that 500 units of
his PCC preparation was not enough to reverse warfarin
with INR >5 [26] ,w ed e c i d e dt oe s t a b l i s ht h ei n i t i a lI N R
Int J Emerg Med (2009) 2:217–225 223of 5 as a cutoff point for increasing the PCC dose to
1,000 units. As part of the Deaconess protocol, our
institution has implemented the administration of vitamin
K concurrent with FEIBA in order to maintain INR
reversal for 12–2 4h[ 27].
Simplifying the weight-adjusted regime suggested by
van Aart et al. [23] who used yet another PCC preparation
of unspecified factor VII activity (Cofact) has the advantage
of shortening the pharmacy turn-around time between order
and drug administration. Following FEIBA administration,
we achieved INR ≤1.4 in 50.7% of patients, compared with
43% reported by van Aart et al. [23]. The Eastbourne group
reported an INR drop to less than 2.0 in 88% of cases
within 2.5 h of PCC administration [19]. We observed a
median drop of INR from 3.3 to 1.5 compared to a drop
from 3.7 to 1.7 reported by van Aart et al. [23].
The use of activated PCC (FEIBA) versus non-activated
PCC preparations raises concerns about a possible higher
incidence of thrombotic events, however, at the same time
suggests a possible higher effectiveness in warfarin reversal
due to more immediate and effective action, which can be
life saving in the setting of an acute bleeding. The
experience with the use of FEIBA in hemophiliac patients
suggests that the incidence of thrombosis in very low,
similar to that of recombinant activated factor VII [22],
which is already being tested as an alternative for warfarin
reversal [9, 10].
Assuming that all five adverse events were indeed due to
thrombotic complications due to FEIBA administration
corresponding to a rate of 7%, which is similar to the
reported risk of 6% with one non-active PCC preparation
(Beriplex) [6] and 7% with another (Proplex T) [13], we
can therefore conclude that the use of an activated PCC
does not increase the risk of thrombosis when compared to
rates reported with the use of non-active PCC preparations.
By assuming that those five adverse events were due to
FEIBA, we are being very conservative, since they may all
have been explained by underlying medical conditions and
not by FEIBA administration. Moreover, since we did not
observe an increased mortality in the FEIBA group, it is
likely that even if this rate of thrombotic events is real, it is
being offset by the benefits of a faster and more effective
warfarin reversal.
The observed mortality rate of 22% is similar to the 19%
reported by van Aart et al. [23], 22% reported by Bruce and
Nokes [12] and 28% reported by Lankiewicz et al. [13].
There was no difference in the survival of patients with
initial INR ≥5 when compared with patients with initial
INR <5. There was also no statistically significant
difference in mortality following FFP administration when
compared to PCC.
Altogether, our results suggest that a low, fixed dose of
FEIBA (i.e., activated PCC) is a relatively safe and efficient
alternative to use instead of higher doses of non-activated
PCC preparations for warfarin reversal in the setting of a
life-threatening bleeding [13, 23]. Moreover, our retrospec-
tive comparison with patients who received FFP supports
previous findings that PCC is superior to FFP for warfarin
reversal in an urgent setting [11, 13]. We observed more
potential adverse effects in the FEIBA group when
compared with the FFP group. It is therefore necessary to
monitor closely for the presence of thrombotic events that
may compromise the benefits of warfarin reversal. However,
this apparent increased incidence of adverse effects did not
increase mortality, nor it did prolong the hospital stay of
patients. Activated PCC delivers activated factor VII for the
reversal of antocoagulation similarly to activated recombinant
factor VII, but at a lower cost. While warfarin itself may soon
become obsolete with the introduction of oral thrombin and
factorX inhibitors[34], PCC has been shown effective in the
reversal of action of those new drugs as well [35]. For
patients such as Jehovah’s Witnesses who refuse transfusion
of plasma and blood products, PCC use is acceptable and
therefore offers a unique life-saving treatment when warfarin
reversal is needed [20].
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